DK1400245T3 - Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering - Google Patents

Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering

Info

Publication number
DK1400245T3
DK1400245T3 DK03255590T DK03255590T DK1400245T3 DK 1400245 T3 DK1400245 T3 DK 1400245T3 DK 03255590 T DK03255590 T DK 03255590T DK 03255590 T DK03255590 T DK 03255590T DK 1400245 T3 DK1400245 T3 DK 1400245T3
Authority
DK
Denmark
Prior art keywords
boric acid
acid salts
parenteral formulations
salts useful
thrombin inhibition
Prior art date
Application number
DK03255590T
Other languages
Danish (da)
English (en)
Inventor
David Jonathan Madge
Mark Dolman
Sophie-Marie Combe-Marzelle
Anthony James Kennedy
Sanjay Kumar Kakkar
John Joseph Deadman
Armin Walter
Alfred Olbrich
Dieter Krimmer
Andrea Maria Th Weiland-Weibel
Original Assignee
Trigen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220764A external-priority patent/GB0220764D0/en
Priority claimed from GB0220822A external-priority patent/GB0220822D0/en
Priority claimed from GB0307817A external-priority patent/GB0307817D0/en
Priority claimed from GB0311237A external-priority patent/GB0311237D0/en
Priority claimed from GB0315691A external-priority patent/GB0315691D0/en
Application filed by Trigen Ltd filed Critical Trigen Ltd
Application granted granted Critical
Publication of DK1400245T3 publication Critical patent/DK1400245T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK03255590T 2002-09-09 2003-09-09 Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering DK1400245T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0220764A GB0220764D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0220822A GB0220822D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0307817A GB0307817D0 (en) 2003-04-04 2003-04-04 Boronic acid compounds
GB0311237A GB0311237D0 (en) 2003-05-16 2003-05-16 Boronic acid compounds
GB0315691A GB0315691D0 (en) 2003-07-04 2003-07-04 Boropeptides
US48578603P 2003-07-08 2003-07-08

Publications (1)

Publication Number Publication Date
DK1400245T3 true DK1400245T3 (da) 2006-08-28

Family

ID=31721886

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03255629T DK1396270T3 (da) 2002-09-09 2003-09-09 Borsyresalte
DK03255590T DK1400245T3 (da) 2002-09-09 2003-09-09 Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03255629T DK1396270T3 (da) 2002-09-09 2003-09-09 Borsyresalte

Country Status (19)

Country Link
EP (8) EP1561466A3 (de)
JP (3) JP2006509034A (de)
KR (2) KR20050057295A (de)
CN (2) CN100447151C (de)
AT (3) ATE324899T1 (de)
AU (3) AU2003263343A1 (de)
BR (1) BR0314450A (de)
CA (3) CA2535792A1 (de)
CY (1) CY1105381T1 (de)
DE (3) DE60304956T2 (de)
DK (2) DK1396270T3 (de)
ES (2) ES2264515T3 (de)
IL (1) IL167294A (de)
MX (2) MXPA05002661A (de)
NZ (2) NZ539333A (de)
PL (2) PL376439A1 (de)
PT (1) PT1396270E (de)
SI (2) SI1396270T1 (de)
WO (3) WO2004022070A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405267D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405280D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
BRPI0815613A2 (pt) * 2007-08-21 2015-03-24 Alza Corp Composições lipossômicas para administração in vivo de compostos de ácido borônico.
CA2697044A1 (en) * 2007-08-21 2009-02-26 Alza Corporation Liposome formulations of boronic acid compounds
WO2009139864A2 (en) * 2008-05-13 2009-11-19 The Regents Of The University Of California Fluorescence detection of poison oak oil
CA2727862C (en) 2008-06-17 2016-04-19 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
AU2009318101A1 (en) * 2008-11-21 2010-05-27 Iroko Cardio Llc Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
WO2010096574A1 (en) 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
CN109187155B (zh) * 2018-07-27 2021-08-13 临沂大学 一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN116940580A (zh) * 2021-03-05 2023-10-24 Agc株式会社 化合物、化合物的制造方法及表面处理剂的制造方法
CN113121666B (zh) * 2021-03-10 2023-09-12 厦门大学 抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) * 2021-10-29 2023-04-18 重庆第二师范学院 一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5856695A (ja) 1981-09-28 1983-04-04 Nitto Boseki Co Ltd 新規なトロンビン測定用基質
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5574014A (en) 1988-04-28 1996-11-12 Thrombosis Research Institute Inhibitors of trypsin-like enzymes
EP0341661A3 (de) 1988-05-11 1991-05-02 The Du Pont Merck Pharmaceutical Company Alpha-Aminoborsäure-Derivate enthaltende Peptid-Mittel Zusammensetzungen
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
US5648338A (en) 1990-11-06 1997-07-15 Thrombosis Research Institute Inhibitors and substrates of thrombin
SK120993A3 (en) 1991-04-30 1994-08-10 Procter & Gamble Liquid detergents with an aryl boronic acid
GB9224702D0 (en) 1992-11-25 1993-01-13 Thrombosis Res Inst Boronic ester synthesis
FR2701951B1 (fr) * 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MY131622A (en) 1993-03-03 2007-08-30 Novartis Ag Organic compounds
AU6448794A (en) * 1993-03-24 1994-10-11 Du Pont Merck Pharmaceutical Company, The Boronic acid and ester inhibitors of thrombin
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
SE9900043D0 (sv) 1999-01-11 1999-01-11 Astra Ab New use
US5681978A (en) * 1993-07-07 1997-10-28 Washington State University Research Foundation Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
WO1995009859A1 (en) * 1993-10-07 1995-04-13 The Du Pont Merck Pharmaceutical Company Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP0805678B1 (de) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9502985D0 (en) 1995-02-16 1995-04-05 Thrombosis Res Inst Enzyme inhibitors
GB9515489D0 (en) 1995-07-28 1995-09-27 Sandoz Ltd Organic compounds
GB9613718D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
GB9724786D0 (en) * 1997-11-25 1998-01-21 Danbiosyst Uk Oral delivery system
WO2001002424A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
SE9904483D0 (sv) 1999-12-08 1999-12-08 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
JP4162491B2 (ja) 2001-01-25 2008-10-08 アメリカ合衆国 ボロン酸化合物製剤
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
EP1400245A1 (de) 2004-03-24
HK1063154A1 (en) 2004-12-17
AU2003263333A1 (en) 2004-03-29
JP2006509034A (ja) 2006-03-16
EP1396270B1 (de) 2006-05-10
JP2006503903A (ja) 2006-02-02
ES2263924T3 (es) 2006-12-16
BR0314450A (pt) 2005-07-26
EP1695711A2 (de) 2006-08-30
WO2004022070A1 (en) 2004-03-18
WO2004022071A1 (en) 2004-03-18
EP1396269A1 (de) 2004-03-10
CN100447151C (zh) 2008-12-31
NZ539333A (en) 2007-02-23
MXPA05002662A (es) 2005-09-20
CN1681517A (zh) 2005-10-12
EP1695712A3 (de) 2008-01-09
EP1466916A1 (de) 2004-10-13
DK1396270T3 (da) 2006-08-28
CN100553639C (zh) 2009-10-28
EP1561466A2 (de) 2005-08-10
CA2535788A1 (en) 2004-03-18
EP1400245B1 (de) 2006-05-03
ATE376551T1 (de) 2007-11-15
EP1561466A3 (de) 2006-08-23
EP1466917A1 (de) 2004-10-13
CN1684693A (zh) 2005-10-19
MXPA05002661A (es) 2005-08-19
PL376535A1 (pl) 2006-01-09
KR20050057295A (ko) 2005-06-16
JP2006511593A (ja) 2006-04-06
EP1466916B1 (de) 2007-10-24
DE60317039D1 (de) 2007-12-06
IL167294A (en) 2008-11-03
CA2536010A1 (en) 2004-03-18
CA2535792A1 (en) 2004-03-18
DE60304956T2 (de) 2007-01-25
EP1695712A2 (de) 2006-08-30
EP1695711A3 (de) 2008-01-02
DE60304956D1 (de) 2006-06-08
CY1105381T1 (el) 2010-07-28
AU2003263343A1 (en) 2004-03-29
SI1400245T1 (sl) 2006-10-31
DE60305113T2 (de) 2006-12-07
ATE325611T1 (de) 2006-06-15
PT1396270E (pt) 2006-08-31
SI1396270T1 (sl) 2006-10-31
KR20050057294A (ko) 2005-06-16
DE60305113D1 (de) 2006-06-14
ATE324899T1 (de) 2006-06-15
AU2003263328A1 (en) 2004-03-29
DE60317039T2 (de) 2008-07-31
WO2004022072A1 (en) 2004-03-18
PL376439A1 (en) 2005-12-27
NZ539334A (en) 2007-11-30
ES2264515T3 (es) 2007-01-01
EP1396270A1 (de) 2004-03-10

Similar Documents

Publication Publication Date Title
DK1400245T3 (da) Borsyresalte anvendelige til parenterale formuleringer til selektiv thrombininhibering
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
WO2004005286A3 (en) Viral inhibitors
NZ337211A (en) Method of treating inflammatory, HIV diseases by using peptidyl boronic acid ester and acid compounds as proteasome inhibitors
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
IS7839A (is) 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
AP2000001900A0 (en) Halogeneted amidino amino acid derivatives useful as nitric oxide synthase inhibitors.
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
SE9803773D0 (sv) Compounds
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
SE0102057D0 (sv) New Salts I
EP1219296A4 (de) Mittel zur hemmung der sebumproduktion
DK0937043T3 (da) Substituerede tetrahydropyridin-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse derivater
SE0102058D0 (sv) New Salts II
ATE286395T1 (de) Antithrombotische mittel
NO20022000L (no) 6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
SE0004827D0 (sv) Therapeutic compounds
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors
CO5271692A1 (es) Agentes terapeuticos
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen